health
Eli Lilly Reaches $2.75 Billion Deal with Insilico to Bring AI-Developed Drugs to the Global Market
U.S. pharmaceutical giant Eli Lilly will give Hong Kong-listed Insilico $115 million upfront to bring some of its AI-discovered drugs to the global market.
TL;DR
- Eli Lilly has agreed to a $2.75 billion deal with Insilico Medicine for AI-developed drugs.
- Insilico will receive $115 million upfront, with additional payments tied to milestones and royalties.
- Insilico has developed at least 28 drugs using generative AI, with many in clinical stages.
- The agreement involves Insilico joining Lilly's Gateway Labs for biotech development.
- Insilico conducts AI development in Canada and the Middle East, with preclinical development in China.
- AI allows for faster molecule synthesis compared to traditional methods.